Except for sick-day protocol, there are no clear guidelines regarding the optimal timing for SGLT-2 inhibitors reinstitution in patients with acute illnesses that might precipitate ketoacidosis.[11] Combination therapy with SGLT-2 inhibitors and metformin is not known as a risk factor for eu-DKA.[3] However, diffuse paralytic ileus is often associated with anorexia, nausea and vomiting, which can decrease calorie or carbohydrate intake. The gene discussed is SLC5A2; the disease is diabetes mellitus.